UTHR United Therapeutics Corporation
Company Analysis
Latest News
🟢 United Therapeutics is trading 4.59% up today after FDA clearance for Phase 2 SUMMIT trial
United Therapeutics is trading at $557.62, up 4.59%, after FDA clearance to start its Phase 2 SUMMIT trial. - On October 19, the FDA cleared the company to...
🟢 United Therapeutics is trading 8.38% up in pre-market with no clear catalyst identified
United Therapeutics is trading at $585.27, up 8.38% versus the October 14 close of $540.03, with no verified overnight announcement or report clearly...
United Therapeutics to Receive $330.4M in Litigation Settlement with Liquidia
United Therapeutics Corporation (UTHR) has entered into a comprehensive settlement agreement with Liquidia Technologies, Inc. to resolve all pending patent...
🔴 United Therapeutics is trading 6.8% down in pre-market
United Therapeutics is trading 6.82% lower at $506.31 in pre-market, with no confirmed company-specific catalyst identified. - The October 13 announcement of...
🔴 United Therapeutics is trading 4.1% down in after-hours trading with no confirmed catalyst
United Therapeutics is trading at $521.12 (-4.10%) in after-hours trading, with no confirmed company-specific news explaining the decline. - On October 13,...
🟢 United Therapeutics is trading 8.55% up in pre-market
United Therapeutics is trading 8.55% higher at $588.02 in pre-market on October 5, with no new company-specific announcement or clearly reported catalyst...
🔴 United Therapeutics is trading 4.1% down today after consecutive sharp gains
United Therapeutics is trading 4.1% lower at $548.07 after consecutive sharp gains; available reporting has not identified a new company-specific catalyst for...
🟢 United Therapeutics gains 4.52% as patent win, analyst upgrade, and share buyback drive momentum
United Therapeutics is trading at $566.39, up 4.52%, continuing its momentum from a September 30 patent ruling. - A Delaware court found Liquidia’s YUTREPIA...
🟢 United Therapeutics is trading 10% up today with no fresh company-specific catalyst identified
United Therapeutics is trading at $531.19, up 10.33%; no fresh company-specific announcement explaining the September 30 surge was identified in available...
🟢 United Therapeutics is trading 9% up today with no company-specific catalyst identified
United Therapeutics is trading at $523.45, up 8.72%, with no fresh company-specific announcement explaining the September 30 move identified in available...
🔴 United Therapeutics is trading 4.03% down today after Goldman Sachs issued a Sell rating
United Therapeutics is trading 4.03% down at $469.68 after Goldman Sachs initiated coverage on September 24, 2026, with a Sell rating and a $321 price target,...
🟢 United Therapeutics is trading 17.3% up in pre-market — catalyst remains unclear
United Therapeutics is trading 17.3% up in pre-market at $578.54, after rising from the September 21 close of $493.10; the catalyst remains unclear. - No...
United Therapeutics Announces $477.6M Accelerated Share Repurchase Agreement
United Therapeutics Corporation has entered into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. to repurchase approximately $477.6 million...
🟢 United Therapeutics is trading 4.6% up in pre-market after a scheduled September 8, 2026 fireside chat
United Therapeutics is trading 4.6% up at $509.80 after executives scheduled a September 8, 2026 fireside chat at the Wells Fargo Healthcare Conference. - The...
🔴 United Therapeutics is trading 4.65% down today; cause remains unclear
United Therapeutics is trading at $488.88, down -4.65%, with the immediate cause unclear. - No clear negative company-specific catalyst was identified for...
United Therapeutics Unveils Pivotal Lung Data, Supporting Recent FDA Filings
United Therapeutics will deliver eight presentations at the European Society of Cardiology (ESC) Congress 2026 and the European Respiratory Society (ERS)...
BlackRock Buys $2.87 Billion United Therapeutics Stake, Signaling Strong Institutional Confidence
BlackRock Inc. acquired 5,294,529 shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter. This investment is valued at approximately...
United Therapeutics Completes Tyvaso Phase 3 Enrollment, Targeting Lung Fibrosis
United Therapeutics completed enrollment for its TETON-PPF Phase 3 study. This multinational trial includes 754 patients to evaluate Tyvaso for the treatment...